Bio-Thera Solutions has started dosing patients in a Phase I clinical trial of BAT4306F to treat relapsed / refractory CD20-positive B-cell non-Hodgkin’s lymphoma.

The Chinese company will evaluate the safety and tolerability of BAT4306F as a single agent as part of the multicentre, open-label, dose-escalation trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is expected to enrol patients with relapsed / refractory CD20-positive B-cell non-Hodgkin’s lymphoma.

Key objectives of the trial comprise identifying maximum tolerated dose, dose-limiting toxicity, pharmacokinetics and recommended doses for subsequent Phase II clinical studies.

“We believe BAT4306F also has great potential as a treatment for other hematologic malignancies.”

Bio-Thera Solutions CEO Shengfeng Li said: “Initiating our Phase I clinical trial for BAT4306F represents a major milestone for Bio-Thera Solutions as BAT4306F is our first clinical candidate developed for the treatment of hematologic malignancies.

“While the BAT4306F development plan will be initially focused on CD20-positive B-cell non-Hodgkin’s lymphoma, we believe BAT4306F also has great potential as a treatment for other hematologic malignancies.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BAT4306F is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced CD20 monoclonal antibody. It has shown improved potential in preclinical studies.

The drug is also a naturally occurring receptor found to be overexpressed in various types of hematologic malignancies.

The solution is currently under development for use as a single agent and in combination with other agents for multiple hematologic malignancies including relapsed / refractory CD20-positive B-cell non-Hodgkin’s lymphoma.